Research programme: antibody cancer therapeutics - Boehringer Ingelheim/Oxford BioTherapeutics

Latest Information Update: 08 Mar 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Oxford BioTherapeutics
Developer Boehringer Ingelheim; Oxford BioTherapeutics
Class Antibodies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Cancer

Most Recent Events

01 Mar 2018 Early research and development is ongoing in United Kingdom
16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
18 Apr 2016 Boehringer Ingelheim exercises an option for exclusive development and commercialisation rights to second cancer antibody drug target

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.